These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3489 related items for PubMed ID: 6958237

  • 1. Phase II study of cyclophosphamide, vincristine and D.T.I.C. +/- B.C.G. in the treatment of malignant melanoma.
    Byrne MJ, Reynolds PM.
    Aust N Z J Med; 1982 Aug; 12(4):263-6. PubMed ID: 6958237
    [Abstract] [Full Text] [Related]

  • 2. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
    Schwarz MA, Gutterman JU, Burgess MA, Heilbrun LK, Murphy WK, Bodey GP, Stone E, Turner-Chism V, Hersh EM.
    Cancer; 1980 May 15; 45(10):2506-15. PubMed ID: 7378986
    [Abstract] [Full Text] [Related]

  • 3. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma.
    Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R.
    Cancer; 1989 Nov 15; 64(10):2024-9. PubMed ID: 2804890
    [Abstract] [Full Text] [Related]

  • 4. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
    Einhorn LH, Furnas B.
    Cancer Treat Rep; 1977 Aug 15; 61(5):881-3. PubMed ID: 329981
    [Abstract] [Full Text] [Related]

  • 5. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
    Cancer; 1989 May 01; 63(9):1676-80. PubMed ID: 2467736
    [Abstract] [Full Text] [Related]

  • 6. Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin.
    Thatcher N, Blackledge G, Palmer MK, Crowther D.
    Eur J Cancer (1965); 1981 Apr 01; 17(4):465-9. PubMed ID: 7308256
    [No Abstract] [Full Text] [Related]

  • 7. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
    Carter RD, Krementz ET, Hill GJ, Metter GE, Fletcher WS, Golomb FM, Grage TB, Minton JP, Sparks FC.
    Cancer Treat Rep; 1976 May 01; 60(5):601-9. PubMed ID: 991149
    [Abstract] [Full Text] [Related]

  • 8. Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas.
    Asai S, Katabami T, Tsuiki M, Tanaka Y, Naruse M.
    Horm Cancer; 2017 Apr 01; 8(2):108-118. PubMed ID: 28108930
    [Abstract] [Full Text] [Related]

  • 9. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
    Presant CA, Bartolucci AA, Smalley RV, Vogler WR.
    Cancer; 1979 Sep 01; 44(3):899-905. PubMed ID: 383276
    [Abstract] [Full Text] [Related]

  • 10. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU, Mavligit GM, Reed R, Burgess MA, Gottlieb J, Hersh EM.
    Cancer Treat Rep; 1976 Feb 01; 60(2):177-82. PubMed ID: 769970
    [Abstract] [Full Text] [Related]

  • 11. Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas.
    Yap BS, Baker LH, Sinkovics JG, Rivkin SE, Bottomley R, Thigpen T, Burgess MA, Benjamin RS, Bodey GP.
    Cancer Treat Rep; 1980 Jan 01; 64(1):93-8. PubMed ID: 7379060
    [Abstract] [Full Text] [Related]

  • 12. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule.
    Pritchard KI, Quirt IC, Cowan DH, Osoba D, Kutas GJ.
    Cancer Treat Rep; 1980 Jan 01; 64(10-11):1123-6. PubMed ID: 7459898
    [Abstract] [Full Text] [Related]

  • 13. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
    Thatcher D, Lind M, Morgenstern G, Carr T, Chadwick G, Jones R, Craig P.
    Cancer; 1989 Apr 01; 63(7):1296-302. PubMed ID: 2646005
    [Abstract] [Full Text] [Related]

  • 14. Treatment of metastatic malignant melanoma with a combination of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388), cyclophosphamide (NSC-26271), and vincristine (NSC-67574).
    Gardere S, Hussain S, Cowan DH.
    Cancer Chemother Rep; 1972 Jun 01; 56(3):357-61. PubMed ID: 19051495
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
    Castel T, Estapé J, Viñolas N, Mascaró JM, Castro J, Vilalta A, Gratacós R, Daniels M, Palou J, Grau JJ.
    Dermatologica; 1991 Jun 01; 183(1):25-30. PubMed ID: 1769411
    [Abstract] [Full Text] [Related]

  • 16. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
    Robidoux A, Gutterman JU, Bodey GP, Hersh EM.
    Cancer; 1982 Jun 01; 49(11):2246-51. PubMed ID: 7042068
    [Abstract] [Full Text] [Related]

  • 17. Metastatic sarcomas: chemotherapy with adriamycin, cyclophosphamide, and methotrexate alternating with actinomycin D, DTIC, and vincristine.
    Presant CA, Lowenbraun S, Bartolucci AA, Smalley RV.
    Cancer; 1981 Feb 01; 47(3):457-65. PubMed ID: 7225999
    [Abstract] [Full Text] [Related]

  • 18. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma.
    Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A.
    Horm Cancer; 2013 Apr 01; 4(2):103-10. PubMed ID: 23361939
    [Abstract] [Full Text] [Related]

  • 19. Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma.
    Green MR, Dillman RO, Horton C.
    Cancer Treat Rep; 1980 Jan 01; 64(1):139-42. PubMed ID: 7379047
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma.
    Verschraegen CF, Legha SS, Hersh EM, Plager C, Papadopoulos N, Burgess MA.
    Eur J Cancer; 1993 Jan 01; 29A(5):708-11. PubMed ID: 8471328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 175.